InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026
Key Highlights
- ➤Izicopan significantly reduced renal injury markers in two hamster kidney disease models
- ➤100 mg/kg izicopan reduced creatinine and BUN after renal ischemia–reperfusion injury
- ➤14-day izicopan dosing significantly reduced BUN and improved histopathology in UUO nephropathy
- ➤Structural modeling suggests izicopan preserves high-affinity C5aR1 binding while reducing CYP3A4/5 interaction
- ➤InflaRx plans izicopan development in ANCA-associated vasculitis and additional renal indications
Expert Statements
Renfeng Guo, Chief Scientific Officer and Founder of InflaRx
“The pre-clinical data presented at Kidney Week demonstrate the ability of izicopan to attenuate renal injury and provide a strong rationale for further development in renal diseases. Combined with its differentiated pharmacokinetic profile, including potentially reduced drug–drug interaction liability, faster onset of action, and more convenient dosing, we believe these results further support izicopan’s best-in-class potential”
Renfeng Guo, Chief Scientific Officer and Founder of InflaRx
“There is an important need for effective, safer treatment options for patients with complement-mediated inflammatory diseases, particularly in renal indications. We are excited to be advancing oral izicopan in ANCA-associated vasculitis as well as in additional kidney diseases.”
* Data from pre-clinical renal disease models demonstrate potential of izicopan for kidney protection * Structural modeling provides new insight into izicopan’s differentiated molecular profile Jena, Germany, Oct. 22, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the presentation of new pre-clinical data on izicopan in renal disease models at the American Society of Nephrology’s Kidney Week 2026, taking place in Denver, Colorado, October 21 - 25. The in vivo and in vitro data demonstrated that izicopan robustly inhibited C5aR-mediated inflammatory responses and provided renal protection, supporting its potential as a therapeutic candidate for complement-driven kidney diseases.
“The pre-clinical data presented at Kidney Week demonstrate the ability of izicopan to attenuate renal injury and provide a strong rationale for further development in renal diseases. Combined with its differentiated pharmacokinetic profile, including potentially reduced drug–drug interaction liability, faster onset of action, and more convenient dosing, we believe these results further support izicopan’s best-in-class potential,” said Renfeng Guo, MD, Chief Scientific Officer and Founder of InflaRx. “There is an important need for effective, safer treatment options for patients with complement-mediated inflammatory diseases, particularly in renal indications. We are excited to be advancing oral izicopan in ANCA-associated vasculitis as well as in additional kidney diseases.”
Get started
Create a free account to read the full story.